← Human Trials & Peer-Reviewed Studies
Incretin hormones, insulin, glucagon and advanced glycation end products in relation to cognitive function in older people with and without diabetes, a population-based study
Plain-language guide to PMID 32020688 (2020): observational study of Glucagon in 2012 people.
Key Facts
- PMID
- 32020688
- Journal
- Diabetic medicine : a journal of the British Diabetic Association
- Year
- 2020
- Study type
- Observational Study
- Authors
- Dybjer E et al. (6 authors)
- DOI
- 10.1111/dme.14267
What This Study Did, in Plain Language
What Was Tested
Researchers studied Glucagon in this observational study publication.
The aim of this observational study was to investigate relationships between physiological levels of glucometabolic biomarkers and cognitive test results in a population-based setting.
Who Took Part
The abstract describes 2012 people taking part.
PubMed indexes the participants as older adults, both men and women.
In 454 participants, advanced glycation end products (AGEs) were estimated through skin autofluorescence.
Associations between biomarkers and two cognitive tests, the Mini-Mental State Examination (MMSE) and A Quick Test of Cognitive Speed (AQT) respectively, were explored in multiple regression analyses.
How the Study Was Run
Cross-sectional data were obtained from the Swedish population-based Malmö Diet and Cancer Study Re-examination 2007-2012 comprising 3001 older people (mean age 72 years).
Through oral glucose tolerance testing (OGTT), fasting and post-load levels of serum insulin, plasma glucagon, serum glucose-dependent insulinotropic peptide (GIP) and plasma glucagon-like peptide-1 (GLP-1) were measured.
Insulin resistance and insulin sensitivity levels were calculated.
What Was Measured
Topics PubMed links to this paper include Blood Glucose, Case-Control Studies, Cognition, Cross-Sectional Studies, Diabetes Mellitus, Gastric Inhibitory Polypeptide and Glucagon.
What This Means in Plain Language
This is an observational study of Glucagon in 2012 people.
With several hundred people or more, it is a fairly large study for this kind of research.
Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2020 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.
More context: the Glucagon compound page, all human trials.
Our Notes on the Compound
Glucagon: A 29-amino-acid pancreatic hormone that raises blood glucose; used as a rescue medicine for severe low blood sugar and as a diagnostic aid.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.